Table 1.

Resistance Levels and Chromosome Aberrations Associated with Acquired Resistance to Platinum Analogues

Cell line: Selection agent	Resistance	Sites of chromosomal imbalance
CH1: cisplatin R.	6.4-fold	+Xq24–28, +4q13–27,+7.
41M: cisplatin R.	4.7-fold	−3q24–29, +4q23–28,−5p12–15.3,+5q11.2–31,+6q16–27,+7p11.2–22, −7q32–36,−9p21,+10q11.2–24,−12q22–24.3.
A2780: cisplatin R.	16-fold	+1q21–23,−1q32–44,+6q21–27,−13q14–34, +17q22–25.
CH1: JM216 R.	6.2-fold	+3p21–26,+12q13–24.1, −18q21–23.
41M: JM216 R.	1.9-fold	+3p23–26, −3q13.2–13.3,+4q21–23,+5p13–q23,+6p12–q12,+6q25–27,−8q13, −9p12–21,+9q22–32,+14q12–13,−14q24–32,+17q21–25.
CHI: AMD473 R.	3- to 4-fold	−Xp21–22.3,+2p14,+4q26–33,+5p14, +6q15–23,+9p21–24,+11q22,+12q13–23,−17p11–13,+20p11.2–q13.3.
A2780: AMD473 R.	3- to 4-fold	−Xp21–22.1,+Xq21, +4q13–31.3,+5q21–23,+6,−7q11.2–21,−10p11.2–13,−12q23–24.1, −17p11–13,+18p11.1–11.3,−20.